Key result
Adding ticagrelor to high-intensity statins linked to ~93% higher risk of muscle complications.
Why the study?
Recent pharmacodynamic studies and case reports suggest potential drug-drug interactions between ticagrelor and high-intensity statins that may increase the risk of adverse muscular and renal complications.
Does the combination of ticagrelor and high-intensity statins increase the risk of muscular complications and acute kidney injury compared to high-intensity statins alone in adult patients?
Cohort (n=577)
No
Does the combination of ticagrelor and high-intensity statins increase the risk of muscular complications and acute kidney injury compared to high-intensity statins alone in adult patients?
Co-administration of ticagrelor and high-intensity statins is associated with a significantly increased risk of muscle-related complications compared to statin monotherapy in a real-world cohort.
Answers are grounded in this paper and cite their sources.
May warrant caution with ticagrelor plus high-intensity statins; hypothesis-generating and requires randomized confirmation.
Introduction: Ticagrelor is a widely used antiplatelet agent approved in over 70 countries, including the European Union and the United States, for reducing thrombotic events in patients with acute coronary syndromes (ACS). In clinical practice, combining ticagrelor with high-intensity statins is considered standard therapy for ACS. However, recent pharmacodynamic studies and case reports suggest potential drug-drug interactions that may increase the risk of adverse events, particularly muscular and renal complications. This study aimed to evaluate these risks in a real-world clinical setting in Saudi Arabia. Methods: This retrospective observational cohort study was conducted at the Makkah Cardiology Center, Saudi Arabia. The study included adult patients (n = 577) who were prescribed high-intensity statins, with or without concurrent ticagrelor. The primary outcomes were the incidence of statin-associated muscular complications-defined as myalgia, myopathy, myositis, or rhabdomyolysis-and acute kidney injury (AKI). Clinical data were extracted from the hospital information system, and statistical comparisons were conducted between patients receiving statin monotherapy and those receiving combination therapy. Results: The cohort consisted predominantly of male patients (74.5%). Muscle-related complications were significantly more common in the group receiving both ticagrelor and statins (20.2%) compared to the statin-only group (10.5%) (P = 0.001). Among comorbid conditions, hypertension was the only factor significantly associated with a higher incidence of muscle-related complications. Although a trend toward increased AKI incidence was observed in the combination therapy group, this difference did not reach statistical significance. Conclusion: This study highlights potential safety concerns related to the co-administration of ticagrelor and high-intensity statins, particularly the increased risk of muscle-related complications. While the findings on AKI were inconclusive, the results support the need for cautious use of this combination and call for larger prospective studies to further evaluate its safety profile and optimize treatment strategies.
No takes yet. Share an insight, caveat, or question.
Alshammari et al. (2025) conducted a cohort in Acute coronary syndromes (n=577). Ticagrelor with high-intensity statins vs. High-intensity statins alone was evaluated on Incidence of statin-associated muscular complications (RR 1.93, p=0.001). Concurrent use of ticagrelor and high-intensity statins increased the risk of muscle-related complications compared to statins alone.
Synapse has enriched 10 related papers. Consider them for comparative context: